Johnson & Johnson Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $97.9B+10.3% YoYTTM through 28 Jun 2026
Net Income $21B+49.6% YoYTTM through 28 Jun 2026
Free Cash Flow $22.2BTTM through 28 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 67.9% |
| EBITDA Margin | 33.6% |
| Operating Margin | 26.8% |
| Net Margin | 21.5% |
Returns
32.9%ROE
13.5%ROA
20.2%ROIC
Balance Sheet Health
Debt / Equity0.60x
Current Ratio1.03x
Net Debt$28.8B
Cash & Equivalents$20.4B
Quality Metrics
Altman Z-Score5.48
Piotroski F-Score7 / 9
FCF Margin22.7%
Rule of 4026.0
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $94.2B
Diluted EPS$8.62TTMFY2025: $11.03
Dividend
$2.64Per share, FY20262.20%Yield-8.8%5-yr growth
Capital Allocation
R&D Spend$109M
Capex Intensity5.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Innovative Medicine | $60.3B | +5.3% | View detailsTargeting sustained long-term growth driven by late-stage pipeline assets and expansion of key therapeutic areas. |
| MedTech | $33.9B | +5.4% | View detailsPoised for accelerated growth through digital surgery platforms and interventional cardiovascular innovations. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.